melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to melanoma cells, nevus cells in serum-free medium require the presence of alpha-melanocyte-stimulating hormone, which enhanced intracellular levels of cyclic adenosine monophosphate.
|
8440904 |
1993 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The human melanocortin-1 (MC1) receptor was stably expressed in the amelanotic mouse melanoma cell clone B16-G4F which does not express its own (mouse) MC1 receptor and hence is unresponsive to alpha melanocyte stimulating hormone (alpha MSH).
|
8856498 |
1996 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha-MSH, a proopiomelanocortin (POMC)-derived peptide, is known to be produced in the pituitary, the skin, and melanoma tumors and to possess many biological effects, mainly on melanocyte pigmentation and growth.
|
9572472 |
1998 |
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
In CRH positive melanomas, seven out of nine cases (78%) of primary melanoma, and 7 out of 12 cases (58%) of MetM showed colocalization of CRH and POMC peptides.
|
11936276 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, melanoma cells synthesize and release alpha-melanocyte stimulating hormone (alphaMSH, the ligand for MC1R), therefore MC1R variants could alter the autocrine effects of alphaMSH on melanoma cell behaviour, thereby affecting early melanoma development and progression via non-pigmentary mechanisms.
|
12439754 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In melanocytes and melanoma cells alpha-melanocyte stimulating hormone (alpha-MSH), via the cAMP pathway, elicits a large array of biological responses that control melanocyte differentiation and influence melanoma development or susceptibility.
|
15983061 |
2005 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Syndecan-2 expression was enhanced by fibroblast growth factor-2, which is known to stimulate melanoma cell migration; however, alpha-melanocyte-stimulating hormone decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner.
|
19641225 |
2009 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An (18)F-labeled linear alpha-MSH peptide ((18)F-FB-Ac-Nle-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH(2) [NAPamide]) shows promising melanoma imaging properties but with only moderate tumor uptake and retention.
|
19837749 |
2009 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the relevance of alpha-melanocyte-stimulating hormone-mediated signaling for the induction of cytotoxicity was assessed in CD8(+) T cells from melanoma patients with functional and nonfunctional melanocortin-1 receptors.
|
20126537 |
2010 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, systemic POMC therapy suppresses melanoma growth via induction of melanogenic differentiation and angiogenesis blockade, thereby demonstrating its potential as a novel treatment modality for melanoma.
|
21126174 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation.
|
21040502 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway.
|
22147647 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that HDGF downregulation participates in POMC-induced suppression of metastasis and EMT in melanoma.
|
23468531 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linking αMSH with PPARγ in B16-F10 melanoma.
|
22863076 |
2013 |
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Because the apoptotic cells were detected mainly in regions distant from blood vessels, it was hypothesized that POMC therapy might render melanoma cells vulnerable to hypoxic insult.
|
24412703 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The importance of the MC1R in reducing UV-induced genotoxicity in melanocytes led us to design small peptide analogs of the physiological MC1R agonist α-melanocortin (α-melanocyte stimulating hormone; α-MSH) for the goal of utilizing them for melanoma chemoprevention.
|
25017567 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes.
|
28578648 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
[Leu<sup>3</sup>, Leu<sup>7</sup>, Phe<sup>8</sup>]-γ-MSH-NH<sub>2</sub> is ideal for inducing short-term skin pigmentation without sun for melanoma prevention.
|
29094944 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linear and cyclic analogues of the α-melanocyte stimulating hormone (α-MSH) targeting the human melanocortin receptor 1 (MC1R) are of pharmacological interest for detecting and treating melanoma.
|
28714883 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radiolabeled linear or cyclic analogs of α-MSH have a great potential as diagnostic or therapeutic tools for the management of malignant melanoma.
|
28491052 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously identified the αMSH/Peroxisome Proliferator Activated Receptor (PPARγ) pathway as a new pathway on the B16-F10 mouse melanoma cell line.
|
29020973 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha melanocyte stimulating hormone (α-MSH) enhances melanogenesis in melanoma malignum by binding to melanocortin-1 receptors (MC1-R).
|
28625749 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
αMSH peptide sequences, evaluated for conjugation to the PEG-Cy5-C' dot nanoparticles, bound to MC1-R with high affinity and targeted melanoma in syngenetic and xenografted melanoma mouse models.
|
29058865 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aim to design and evaluate αMSH derivatives that enable radiolabeling with <sup>18</sup>F for PET imaging of melanoma.
|
29714486 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma.
|
29182034 |
2018 |